Arrowhead Pharmaceuticals Plozasiran Meets Phase 3 Endpoints

What happened

Arrowhead Pharmaceuticals announced topline results from two global Phase 3 trials, SHASTA-3 and SHASTA-4, evaluating plozasiran in patients with severe hypertriglyceridemia (sHTG). Both studies met their primary endpoint of triglyceride reduction versus placebo and achieved all prespecified secondary endpoints. Patients receiving 25 mg of plozasiran once every three months saw median triglyceride reductions of 79% and 81% at 12 months, compared to approximately 27% in placebo groups. A pooled analysis showed a 78% reduction in acute pancreatitis events versus placebo. The drug continued to demonstrate favorable safety and tolerability, with no clinically meaningful changes in liver enzymes, blood platelet counts, or hypersensitivity reactions. Plozasiran is already approved under the brand name Redemplo for familial chylomicronemia syndrome (FCS), a rare genetic disorder affecting approximately 6,500 people in the US. Arrowhead plans to submit a supplemental new drug application (sNDA) to the FDA before year-end to expand the drug's label to include severe hypertriglyceridemia.

Why it matters

Severe hypertriglyceridemia significantly increases the risk of acute pancreatitis, a condition associated with repeated hospital admissions and potential fatality. The positive Phase 3 results position plozasiran as a competitive treatment option in this indication, particularly given its quarterly dosing schedule compared to monthly administration required by rival therapies. Analysts view the data as a best-case scenario, noting that the drug's safety profile and efficacy could enable it to capture significant market share. The lack of meaningful increases in liver fat-a side effect observed with competing treatments-may serve as a key differentiator. Securing FDA approval for this expanded indication would substantially broaden plozasiran's addressable patient population beyond the rare FCS indication.

Bigger picture

The success of plozasiran in severe hypertriglyceridemia puts Arrowhead in direct competition with Ionis Pharmaceuticals' Tryngolza, which received FDA approval for this indication first. Analysts suggest that despite Tryngolza's head start, plozasiran's comparable efficacy, favorable safety profile, and dosing convenience position it to compete effectively for market share. The RNA therapeutics sector continues to demonstrate its potential in addressing metabolic disorders, with genetic medicines targeting specific proteins involved in disease pathways. Arrowhead's approach-degrading instructions cells use to create a protein that slows triglyceride metabolism-represents a broader trend toward precision medicine. The company has already secured regulatory approvals for plozasiran in the US, Europe, Australia, and Canada for FCS treatment.

What to watch

Arrowhead will present detailed Phase 3 trial data at the ESC 2026 conference on August 30, 2026, which will provide more comprehensive insights into safety and efficacy profiles. The company's sNDA submission to the FDA before year-end will be a critical milestone, with approval timing and any label restrictions being key factors for commercialization. Investors should monitor the company's third-quarter earnings announcement on August 4, 2026, for updates on financial performance and commercial strategy. Comparative analyses with Tryngolza, particularly regarding liver fat effects and real-world efficacy, will influence physician prescribing patterns and market positioning. Additionally, any updates on manufacturing scale-up and commercial launch preparations will be important for assessing revenue potential.